Indiana Governor Mike Braun has indicated a significant shift in his stance on cannabis policy, suggesting that federal rescheduling of cannabis makes state-level legalization more probable. This evolving perspective comes as a new study by RAND, commissioned by the Richard M. Fairbanks Foundation, illuminates the substantial economic and enforcement implications of Indiana’s current prohibition, providing critical data for future medical cannabis policy discussions.
Governor Braun’s Evolving Stance on Medical Cannabis Policy
Governor Braun, a Republican, recently expressed a growing willingness to consider cannabis legalization, acknowledging that Indiana is “surrounded” by states that have implemented some form of cannabis reform. Neighboring states such as Illinois, Michigan, and Ohio permit recreational use, while Kentucky has authorized medicinal use. “I’m going to do what makes sense,” Braun told reporters, as reported by Marijuana Moment. He emphasized the importance of input from law enforcement and the noticeable cross-border traffic by Hoosiers seeking legal cannabis products.
A key factor influencing the Governor’s updated perspective is the recent federal rescheduling of medical cannabis to a less restrictive category. While recreational use remains in a higher schedule, the administrative process for re-evaluating this classification has begun. “I think the fact that the feds made that move, that makes it more likely,” Braun stated, indicating that federal action could pave the way for state-level changes. This marks a notable progression from his 2024 gubernatorial campaign, where he had expressed openness to medical-use sales but not recreational, according to Fox59 via Marijuana Moment.
Economic and Enforcement Realities in Indiana
The Governor’s comments coincided with the release of two comprehensive reports by RAND, conducted on behalf of the Richard M. Fairbanks Foundation, aimed at providing data on cannabis and intoxicating cannabinoids in Indiana. Emi Whitesell, Vice President of Impact and Evaluation at Fairbanks, noted that the research was commissioned to address a data gap specific to Indiana, as much existing research focuses on states with established medical cannabis programs.
The studies reveal significant economic activity within Indiana’s unregulated cannabis sector. Indiana residents spend an estimated US$1.8 million annually on marijuana, according to Marijuana Moment, while Ganjapreneur reported this figure as nearly $2 billion. Concurrently, the state’s criminal justice system allocates between US$10 million and US$20 million annually for cannabis law enforcement. Despite prohibition, intoxicating cannabinoids like delta-8 THC and THCA are widely available due to a lack of state regulation, a situation researchers described as “ubiquitous.”
The reports also highlight the accessibility of legal cannabis for Hoosiers in neighboring states:
- 44 percent of Indiana residents live within a 50-mile drive of at least one licensed dispensary in another state.
- 96 percent of residents live within a 100-mile drive of a licensed dispensary.
This means nearly all Hoosiers can access retail cannabis with a roundtrip drive of under four hours, underscoring the practical challenges of maintaining prohibition, as previously reported by Hemp Gazette regarding Indiana’s illegal cannabis market.
Policy Pathways and Potential Fiscal Impact
The RAND studies explored various policy routes Indiana could pursue, ranging from maintaining the current prohibition to fully legalizing recreational use. Intermediate options include reducing criminal penalties for possession, such as treating it as a low priority, reducing fines or jail time, or replacing criminal penalties with civil citations for small amounts. Additionally, the state could facilitate or automate the expungement or sealing of past cannabis-related convictions.
Should Indiana opt to legalize medical or recreational cannabis, the reports outline numerous policy decisions. For a recreational market, 14 major decisions would be required, including licensing for cultivation, refining, and sales, and determining taxation levels. A medical cannabis system would involve these considerations plus four additional factors:
- Qualifying medical conditions.
- Authorized medical professionals for recommendations.
- Cost of patient licenses.
- Methods for patients unable to travel or cultivate to procure cannabis.
While legalization would introduce new costs for licensing, inspections, and testing, researchers estimated a potential annual tax revenue of US$180 million by the fifth year of implementation, representing approximately 1 percent of the state’s US$18 billion General Fund. This revenue could range from US$100 million to US$270 million, depending on various market factors, as detailed by Marijuana Moment. Even with legalization, enforcement costs would persist for issues like driving under the influence and underage possession.
Disclaimer: This article is for informational purposes only and does not constitute medical advice. Hemp Gazette does not provide medical recommendations, diagnoses, or treatment plans. Always consult a qualified healthcare practitioner before making any decisions regarding your health or any medical condition. Statements concerning the therapeutic uses of hemp, cannabis, or cannabinoid-derived products have not been evaluated by Australia’s Therapeutic Goods Administration (TGA). Medicinal cannabis products in Australia are accessed via prescription pathways under TGA regulation.
